A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been a prominent target among clinical trials in recent years, with 15 assets currently in Phase 3 for various cancer types (Kognitic, 2019). However, considering this recent finding, PD-L1 may soon replace PD-1 as a leading target for clinical trials. It may also foreshadow increased future revenue for companies with PD-L1 antibodies currently in Phase 3. Kognitic’s dynamic platform can provide in-depth pipeline views for all targets, such as PD-L1, in real-time, enabling clients to assess the competition across all indications!
#Oncology hashtag#Pipeline hashtag#PD1 hashtag#Insights hashtag#Cancer hashtag#ArtificalIntelligence hashtag#ClinicalTrials hashtag#PDL1 hashtag#MachineLearning hashtag#Visuals hashtag#Automation hashtag#Antibodies hashtag#CompetitiveIntelligence hashtag#kognitic
Comments are closed.